RT Journal Article
T1 In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives
A1 Moreno-Viguri, Elsa
A1 Jimenez-Montes, Carmen
A1 Martin-Escolano, Ruben
A1 Santivanez-Veliz, Mery
A1 Martin-Montes, Alvaro
A1 Azqueta, Amaya
A1 Jimenez-Lopez, Marina
A1 Zamora Ledesma, Salvador
A1 Cirauqui, Nuria
A1 Lopez de Cerain, Adela
A1 Marin, Clotilde
A1 Sanchez-Moreno, Manuel
A1 Perez-Silanes, Silvia
K1 Iron superoxide-dismutase
K1 Polymerase-chain-reaction
K1 Chagas-disease
K1 Potential antidepressants
K1 Serotonin transporter
K1 Imidazole rings
K1 Maesa-balansae
K1 Force-field
K1 Infection
K1 Benznidazole
AB Chagas disease is a neglected tropical disease with 6-7 million people infected worldwide, and there is no effective treatment. Therefore, there is an urgent need to continue researching in order to discover novel therapeutic alternatives. We present a series of arylaminoketone derivatives as Means of identifying new drugs to treat Chagas disease in the acute phase with greater activity, less toxicity, and a larger spectrum of action than that corresponding to the reference drug benznidazole. Indexes of high selectivity found in vitro formed the basis for later in vivo assays in BALB/c mice. Murine model results show that compounds 3, 4, 7, and 10 induced a remarkable decrease in parasitemia levels in acute phase and the parasitemia reactivation following immunosuppression, and curative rates were higher than with benznidazole. These high antiparasitic activities encourage us to propose these compounds as promising molecules for developing an easy to synthesize anti-Chagas agent.
PB Amer chemical soc
SN 0022-2623
YR 2016
FD 2016-12-22
LK http://hdl.handle.net/10668/18897
UL http://hdl.handle.net/10668/18897
LA en
DS RISalud
RD Jul 30, 2025